Pyxis Oncology, Inc. (PYXS) — Congressional trading
Health Care · NASDAQ
Pyxis Oncology is a clinical-stage biopharma developing innovative antibody-drug conjugates (ADCs) that target the tumor microenvironment to improve efficacy in difficult-to-treat…
As of 2026-07-23, no U.S. House member has disclosed trading Pyxis Oncology, Inc. (PYXS) in our data (STOCK Act Periodic Transaction Reports).
We match U.S. House Clerk STOCK-Act Periodic Transaction Reports to covered companies; a company can have no reported Congressional trades, or its disclosures may not yet be in our data. You can always check the primary source directly via the House Clerk link above, or see the full company profile.
More on Pyxis Oncology, Inc.: company profile · insider trading · SEC filings · similar companies.
Source: U.S. House Clerk Periodic Transaction Reports (PTRs) filed under the STOCK Act. Disclosure can lag the actual trade by up to 45 days, so these are not real-time. Amounts are broad ranges as legally required — not exact figures. A transaction may belong to the member, their spouse, or a dependent child (see the owner column); a spouse or dependent trade is not the member's personal trade. This information is reused from the official public disclosure record for informational and public-interest (news) purposes only. Informational only — NOT financial advice, and NOT a signal to buy or sell.
Informational only — NOT financial advice. Congressional disclosures are sourced from the U.S. House Clerk public financial-disclosure archive.